Suggested Topics within your search.
Showing 121 - 140 results of 380 for search '"Johns Hopkins University"', query time: 0.06s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124
  5. 125
  6. 126

    Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era by Ayotola Fatola, Michael D. Evans, Jenna Brown, Elizabeth Davis, Andrew Johnson, Ana G. Antun, Andrew M. Farland, Ryan Woods, Ara Metjian, Yara A. Park, Gustaaf de Ridder, Briana Gibson, Raj S. Kasthuri, Darla K. Liles, Susan Eubanks, Frank Akwaa, Todd Clover, Lisa Baumann Kreuziger, J. Evan Sadler, Meera Sridharan, Ronald S. Go, Keith R. McCrae, Harsh Vardhan Upreti, Ming Y. Lim, Nicole K. Kocher, Radhika Gangaraju, X. Long Zheng, Jay S. Raval, Camila Masias, Spero R. Cataland, Marshall Mazepa, Shruti Chaturvedi

    Published 2025-01-01
    “…Separately, we evaluated overall RFS (composite of time to clinical relapse, ADAMTS13 relapse, or preemptive rituximab) in a prospective iTTP cohort from the Johns Hopkins University and the University of Minnesota. In the USTMA registry, median clinical RFS was shorter after the second or subsequent rituximab-treated episode than the first (2.1 vs 6.0 years; P = .04). …”
    Get full text
    Article
  7. 127
  8. 128
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135
  16. 136
  17. 137
  18. 138
  19. 139
  20. 140